

Summary of Product Characteristics for Fluconazole

Trade Name of the Medicinal Product: Gynofloran 50mg, 150mg. Qualitative and Quantitative Composition: Fluconazole 50mg, 150mg

Pharmaceutical Form: Capsules.

Therapeutic indications: Treatment of: Genital candidiasis including vaginal candidiasis, acute or recurrent; Candidal balanitis. Consider

the treatment of partners who present symptomatic genital candidiasis; Mucosal candidiasis including oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth); Systemic candidiasis such as candidaemia, disseminated candidiasis and other forms of invasive candidal infection of the peritoneum, endocardium and pulmonary and urinary tracts; Candidal infections in patients with malignancy, in intensive care units or those receiving cytotoxic or immunosuppressive therapy; Cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous); Maintenance therapy to prevent relapse of cryptococcal disease in patients with AIDS; Tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections. Fluconazole is not indicated for nail infections. Prevention of: Fungal infections in immunocompromised patients considered at risk as a consequence of neutropenia following cytotoxic chemotherapy or radiotherapy, including bone marrow

transplant patients. Use in children: Fluconazole should not be used for tinea capitis.

Contraindications: Hypersensitivity to fluconazole or to related azole compounds or to any other ingredient within the formulation.

Concomitant use with terfenadine or cisapride.

Special warnings and precautions for use: Abnormalities in the results of haematological, hepatic, renal and other biochemical function; Hepatotoxicity;

Renal impairment; In rare cases, as with other azoles, anaphylaxis has been reported.

Interactions with other medicinal products Anticoagulants; Benzodiazepines; Sulphonylureas; Phenytoin; Hydrochlorothiazide; Theophylline; Rifampicin; Ciclosporin; Terfenadine; Zidovudine; Rifabutin; Cisapride; Tacrolimus; Astemizole, or other drugs metabolised

and other forms of interaction: by the cytochrome P450.

Undesirable effects:

Fluconazole should not be used in pregnancy, or in women of childbearing potential, unless adequate Pregnancy and lactation:

contraception is employed. Use in nursing mothers is not recommended.

Headache, rash, abdominal pain, diarrhoea, flatulence and nausea, hepatic toxicity changes in renal and haematological function test results, dizziness, seizures, alopecia, exfoliative skin disorders including Stevens-Johnson syndrome and toxic epidermal necrolysis, vomiting, leukopenia including neutropenia and agranulocytosis, thrombocytopenia, anaphylaxis (including angiodema, face oedema, pruritus), hepatic failure,

hepatitis, hepatocellular necrosis, jaundice, hypercholesterolaemia, hypertriglyceridaemia, hypokalaemia, taste

perversion, QT prolongation, torsade de pointes.

MAH: Codal-Synto Ltd.





Gynofloran® Fluconazole

GYNOFLORAN 50mg capsules GYNOFLORAN 150mg capsules

Drug Classes and Mechanisms of Action

Class	Mechanism of action	Drugs	
Allylamine	Inhibits squalene epoxidase	Terbinafine	
Azole	Impairs ergosterol synthesis	Ketoconazole	
		Fluconazole	
		Itraconazole	
		Voriconazole	
Echinocandin	Impairs ß 1,3 glucan synthesis	Caspofungin	
Nucleoside analog	Impairs pyrimidine metabolism	Flucytosine	
Polyene	Binds to ergosterol	Amphotericin B deoxycholate	
		Amphotericin B colloidal dispersion	
		Amphotericin B lipid complex	
		Liposomal amphotericin B	

David S. McKinsey, MD; Making Best Use of the Newer Antifungal Drugs Posted: 09/23/2003; © 2003 Cliggott Publishing, Division of CMP Healthcare Media

⁴ An change and cha

General Patterns of Susceptibility of Candida Species Effective treatment for fungal infections

Candida Species	Fluconazole	Itraconazole	Flucytosine	Amphotericin B
C. Albicans	S	S	S	S
C. Tropicalis	S	S	S	S
C. Parapsilosis	S	S	S	S
C. Glabrata	S-DD to R	S-DD to R	S	S-I
C. Krusei	R	S-DD to R	I-R	S-I
C. Lusitaniae	S	S	S	S to R
C. Kefyr	S	S	S	S
C. Guilliermondii	S	S	S	S-R
C. Dubliniensis	S	S	S	S

I - intermediate; R - resistant; S - susceptible; S-DD - susceptible dose dependent.

Jose A. Vazquez, MD, FACP, FIDSA; Treatment of Candidiasis in Hospitalized Patients. Current Treatment Options in Infectious Diseases 2003, 5:495506



